• Nenhum resultado encontrado

Estrogen receptor status in relation to risk of contralateral breast cancer-a population-based cohort study.

N/A
N/A
Protected

Academic year: 2017

Share "Estrogen receptor status in relation to risk of contralateral breast cancer-a population-based cohort study."

Copied!
8
0
0

Texto

Loading

Imagem

Figure 1. Nelson –Aalen plots. Cumulative incidence of CBC for women with ER-negative vs
Table 3. Standardized incidence ratios (SIR) comparing the incidence of ER-positive and ER-negative CBC to the incidence of unilateral breast cancer, overall and according to ER-status of the first breast cancer, for all patients and stratified on age.
Table 5. Number of women at risk of CBC by year after diagnosis, subdivided on ER-status of the first cancer.

Referências

Documentos relacionados

HORMONE REPLACEMENT THERAPY AND THE RISK OF BREAST CANCER: ASSESSMENT OF THERAPY ACCEPTANCE IN A COHORT OF PREVIOUSLY TREATED BREAST CANCER PATIENTS.. Agnaldo Anelli,

In this chapter main curriculums will be presented and than a major research will be made over IB (International Baccalaureate) and CIE (Cambridge International Examination),

Mas a marionete existe, mesmo que o seu nome não satisfaça a todos, como Fabrizio Montecchi disse para a sombra: falamos sobre ela, mas sem saber realmente o que é.... O principal é

Distribution of variables according to the nature of the health care service (proxy of socioeconomic status) for the 437 women included in the breast cancer hospital-based cohort,

The small number of breast cancer cases exposed to 5ARIs and the lack of an association in our study suggest that the development of breast cancer should not in- fluence

first occurrence of breast cancer in cohort studies and in case-control studies with the appearance of the first breast cancer; (c) mean follow-up time – minimum of ten years

with risk of postmenopausal breast cancer in the Iowa women’s health study. Cancer Epidemiol

Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. Biology of HER2 and its importance in